Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBPBiotechnology
+$0.14 today
- Market cap
- $56.57M
- Beta
- 2.59
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$6.35
Volume 0.63M
Average 0.42M
CRBP Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $22.97M (cash outflow) rose 35.3% year over year, behind the +68.1% change in trailing-twelve-month net income. Sequentially, it rose 11.7% from the prior quarter. Over 3 fiscal years it compounded at +22.9% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 8 analysts of -$80.29M (+2.2%) for the fiscal year ending Dec 2026, a slowdown from the +95.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$22.97M+11.7% QoQ
- Last fiscal yearDec 2025
- -$78.54M+95.3% YoY
- LTMMar 2026
- -$84.53M+68.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +35.3% | +38.3% | +3.0 pp |
| 1 year | +95.3% | +2.2% | -93.1 pp |
| 3-year CAGR | +22.9% | -9.2% | -32.0 pp |
| 5-year CAGR | -35.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (78.54M) USD
- Year-over-year change
- -95.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (78.54M) | -95.3% |
| FY2024 | 2024-12-31 | (40.21M) | +9.9% |
| FY2023 | 2023-12-31 | (44.6M) | -5.3% |
| FY2022 | 2022-12-31 | (42.35M) | +7.2% |
| FY2021 | 2021-12-31 | (45.64M) | — |
Net Income vs competitors
How CRBP compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +68.1% is the 2nd highest of 10, against a peer median of -0.6%.
- Over three fiscal years its annual growth of +22.9% compares with a peer median of +4.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $125.39M USD | +1.6% | +2.3% | 680.8% | |
| LTM Mar 2026 | $84.53M USD | +68.1% | +22.9% | — | |
| LTM Mar 2026 | $77.22M USD | -24.4% | +9.1% | — | |
| LTM Mar 2026 | $75.86M USD | +73.5% | +71.0% | — | |
| LTM Mar 2026 | $68.36M USD | +31.7% | +2.6% | 3832.0% | |
| LTM Mar 2026 | CHF 64.16M CHF | +7.8% | — | — | |
| FY2025 | €49.18M EUR | -0.6% | -5.4% | 1764.5% | |
| LTM Mar 2026 | $44.76M USD | -8.4% | +5.8% | 8526.1% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $40.19M USD | -21.6% | +11.9% | — |
| LTM Mar 2026 | $31.7M USD | -25.4% | -22.3% | 1000.2% | |
| Peer median (excluding CRBP) | — | -0.6% | +4.2% | 1764.5% | |
Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (45.64M) | (42.35M) | (44.6M) | (40.21M) | (78.54M) |
| Depreciation & Amortization | 1.64M | 1.49M | 641K | (2.74M) | (1.13M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 9.48M | 5.72M | 3.47M | 6.15M | 6.29M |
| Change in Working Capital | (15.7M) | (4.02M) | 4.09M | (5.58M) | 9.12M |
| Accounts Receivables | 1.62M | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (5.96M) | (256.84K) | 1.03M | 1.6M | (2.35M) |
| Other Working Capital | (11.36M) | (3.77M) | 3.07M | (7.18M) | 11.47M |
| Other Non-Cash Items | 2.03M | 1.62M | 3.77M | 585K | (229K) |
| Operating Cash Flow | (48.18M) | (37.54M) | (36.1M) | (41.79M) | (64.49M) |
| Capital Expenditures | (54.17K) | (13.45K) | 3 | 0 | (7K) |
| Acquisitions (Net) | 0 | 8.1K | 0 | 0 | 0 |
| Purchases of Investments | (87.27M) | (86.34M) | (33.88M) | (180.8M) | (163.09M) |
| Sales of Investments | 13.88M | 116.42M | 69.53M | 59.49M | 161.46M |
| Other Investing Activities | 23.9K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (73.42M) | 30.07M | 35.64M | (121.31M) | (1.64M) |
| Debt Repayment | 57.78K | (533.62K) | (2.87M) | (15.48M) | 0 |
| Common Stock Issued | 62.59M | 0 | 53.4K | 182.06M | 77.43M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.82M) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 60.82M | (533.62K) | (2.82M) | 166.58M | 77.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (60.78M) | (8M) | (3.28M) | 3.47M | 11.29M |
| Free Cash Flow | (48.24M) | (37.56M) | (36.1M) | (41.79M) | (64.5M) |
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
Intrinsic Alpha fair value
Locked
Current Price
$2.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.